Based on the results of Phase III clinical trials, the anti-tumour necrosis factor alpha (anti-TNFα) monoclonal antibody adalimumab has also been added to the therapeutic armamentarium for moderate to severe HS [24]. Here, TNF is linked to histiocytic sarcoma.